{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:12:24Z","timestamp":1692850344788},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12253-017-0234-2","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T06:15:06Z","timestamp":1492755306000},"page":"199-205","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)"],"prefix":"10.1007","volume":"24","author":[{"given":"Tam\u00e1s","family":"Schneider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Rosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajna","family":"Losonczy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1sp\u00e1r","family":"Radv\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"Ujj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikl\u00f3s","family":"Egyed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Jakucs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Szerafin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Gasztonyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Iv\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Demeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Dombi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antal","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zita","family":"Borb\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"issue":"5","key":"234_CR1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40273-013-0043-8","volume":"31","author":"J Greenhalgh","year":"2013","unstructured":"Greenhalgh J, Bagust A, Boland A et al (2013) Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: a NICE single technology appraisal. PharmacoEconomics 31(5):403\u2013413","journal-title":"PharmacoEconomics"},{"issue":"10","key":"234_CR2","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","volume":"4","author":"CJ Gallagher","year":"1986","unstructured":"Gallagher CJ, Gregory WM, Jones AE et al (1986) Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4(10):1470\u20131480","journal-title":"J Clin Oncol"},{"key":"234_CR3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LD Piro","year":"1990","unstructured":"Piro LD, White CA, Grillo-L\u00f3pez AJ et al (1990) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol 10:655\u2013661","journal-title":"Ann Oncol"},{"key":"234_CR4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","volume":"15","author":"TF Tedder","year":"1994","unstructured":"Tedder TF, Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15:450\u2013454","journal-title":"Immunol Today"},{"key":"234_CR5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435\u2013445","journal-title":"Blood"},{"key":"234_CR6","first-page":"637a","volume":"88","author":"D Maloney","year":"1996","unstructured":"Maloney D, Smith B, Appelbaum F (1996) The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apopthosis in CD20 positive non-Hodgkin\u2019s lymphoma (NHL) cell lines. Blood 88:637a","journal-title":"Blood"},{"key":"234_CR7","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK et al (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457\u20132466","journal-title":"Blood"},{"key":"234_CR8","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825\u20132833","journal-title":"J Clin Oncol"},{"key":"234_CR9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","volume":"17","author":"MS Czuczman","year":"1999","unstructured":"Czuczman MS, Grillo-Lopez AJ, White CA et al (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268\u2013276","journal-title":"J Clin Oncol"},{"key":"234_CR10","unstructured":"Czuczman MS, Fallon A, Mohr A et al (2001) Phase II study of rituximab plus fludarabine in patients (pts) with low-grade lymphoma (LGL): final report. ASH 2001 Abstr no.: 2518"},{"key":"234_CR11","unstructured":"Hiddemann W, Dreyling MH, Forstpointner R et al (2003) Combined Immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). ASH Abstr no.: 352"},{"key":"234_CR12","unstructured":"Marcus R, Imrie K, Belch A et al (2003) An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III\/IV follicular non-Hodgkins lymphoma. ASH Abstr no.: 87"},{"key":"234_CR13","unstructured":"Dreyling MH, Forstpointner R, Repp R et al (2003) Combined Immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma final results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). ASH Abstr. No.: 351"},{"key":"234_CR14","first-page":"564","volume":"22","author":"P McLaughlin","year":"2003","unstructured":"McLaughlin P, Rodriguez MA, Hagemeister FB et al (2003) Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance. Proc am Soc Clin Oncol 22:564","journal-title":"Proc am Soc Clin Oncol"},{"key":"234_CR15","unstructured":"Vitolo U, Boccomini C, Ladetto M et al (2002) High clinical and molecular response rate in elderly patients with advanced stage follicular lymhoma treated at diagnosis with a brief chemo-immunotherapy FND + rituximab. ASH Abstr no.: 1392"},{"key":"234_CR16","unstructured":"Gregory SA, Venugopal P, Adler S et al (2003) A phase II study of fludarabine phosphate and mitoxantrone followed by anti-CD20 monoclonal antibody in the treatment of patients with newly diagnosed, advanced low-grade non-Hodgkin\u2032s lymphoma (LGNHL): interim results ASH Abstr no.:1499"},{"issue":"4","key":"234_CR17","first-page":"694","volume":"23","author":"MS Czuczman","year":"2005","unstructured":"Czuczman MS, Koryzna A, Mohr A et al (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005 23(4):694\u2013704","journal-title":"J Clin Oncol 2005"},{"key":"234_CR18","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma. J Clin Oncol 15:3266\u20133274","journal-title":"J Clin Oncol"},{"key":"234_CR19","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"key":"234_CR20","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-Lopez AJ, White CA et al (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18:3135\u20133143","journal-title":"J Clin Oncol"},{"key":"234_CR21","unstructured":"Hainsworth JD, Litchy S, Morrissey L et al (2003) Rituximab as first-line and maintenance therapy for indolent non-Hodgkin\u2032s lymphoma (NHL): long-term follow-up of a minnie pearl cancer research network phase II trial. ASH Abstr no.: 1496"},{"issue":"12","key":"234_CR22","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SFH, Cogliatti SB et al (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103(12):4416\u20134423","journal-title":"Blood"},{"issue":"10","key":"234_CR23","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster H, Weller E, Gascoyne RD et al (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009 27(10):1607\u20131614","journal-title":"J Clin Oncol 2009"},{"issue":"10","key":"234_CR24","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE et al (2006) Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108(10):3295\u20133301","journal-title":"Blood"},{"issue":"9759","key":"234_CR25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"GL Salles","year":"2011","unstructured":"Salles GL, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42\u201351","journal-title":"Lancet"},{"issue":"17","key":"234_CR26","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH Oers van","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L et al (2010) Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28(17):2853\u20132858","journal-title":"J Clin Oncol"},{"issue":"21","key":"234_CR27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V122.21.509.509","volume":"122","author":"GL Salles","year":"2013","unstructured":"Salles GL, Seymour JF, Feugier P et al (2013) Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline Immunochemotherapy. Blood 122(21):509","journal-title":"Blood"},{"issue":"suppl 5","key":"234_CR28","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","volume":"27","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Ghielmini M, Rule S et al (2016) ESMO guidelines committee. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v83\u2013v90","journal-title":"Ann Oncol"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-017-0234-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-017-0234-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-017-0234-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T06:39:29Z","timestamp":1692772769000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-017-0234-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["234"],"URL":"https:\/\/doi.org\/10.1007\/s12253-017-0234-2","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,21]]}}}